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144 have the absolute difference between CSS 1 and CSS 2 lower than 10, resulting in a total of 18,905 145 drug combinations. After this filtering the correlation between CSS 1 and CSS 2 was further improved 146 (Pearson correlation = 0.93, p-value = 2×10 -16 ). Furthermore, the mean absolute difference between 147 CSS 1 and CSS 2 was 3.83, which became comparable to the variability determined from the technical 148 replicates of CSS 1 and CSS 2 (2.92 and 3.06 respectively), suggesting that the difference between CSS 1 149 and CSS 2 is similar to what is expected when repeating the experiment. Taken together, CSS 1 and 150 CSS 2 values are highly consistent and therefore supported their averaging as a summary for the drug 151 combination sensitivity score.
152 CSS can be predicted using machine learning approaches
153
Given that the CSS is highly reproducible as a summary of the overall sensitivity of a drug 154 combination, we explored whether CSS can be predicted using pharmacological and chemical 155 information of the drugs. We considered a drug combination as a combination of its drugs target 156 profiles as well as their chemical fingerprints, with which the machine learning approaches 157 illustrated in the previous section can be optimized by exploring the feature space using the training 158 data. We examined three major machine learning methods for predictions: Elastic Net, Random 159 Forests and Support Vector Machines.
160
We found that all of these machine learning approaches worked reasonably well, with the 161 Elastic Net consistently achieving the best performance, with the mean MAE of 4.01 which is 162 comparable to that (2.07) of a technical replicate ( Table 1 ). Note that in our cross-validation setting 163 the drug combinations in the test data were not present in the training data, the machine learning 164 methods were still able to predict the CSS values for new drug combinations by exploring the feature 165 similarity in the drug targets and chemical fingerprints. The prediction performance thus validated 8 167 profiles and chemical-structural properties, with which the CSS score can be predicted with high 168 confidence using the state-of-the-art machine learning approaches.
169 259 true antagonistic drug combinations. We then asked the question of whether the CSS-based synergy 260 scores that were determined using the cross design can predict the ground truth. We showed that 261 the CSS-based synergy scores managed to achieve the area under the ROC curves of 0.997 (S sum ), 262 0.996 (S max ) and 0.992 (S mean ) to detect the true synergistic and antagonistic combinations correctly 263 (Fig 3A) . Note that in order to calculate the synergy score, only two vectors of the drug combination 264 responses are needed, rather than the full dose-response matrix. Therefore, the CSS-based synergy 265 score needs a substantially fewer measurements compared to the other well-established synergy 266 scores. Still, the CSS-based synergy scores can predict the most synergistic and antagonistic drug 267 combinations with high accuracy. On the other hand, the CSS-based synergy score and the CSS drug 268 combination sensitivity score were using the same unit as the percentage of the actual drug 269 response compared to the theoretical upper limit. Therefore, the synergy score can be interpreted 270 as the extra benefit of combining two drugs that can achieve an effect closer to the upper limit. We 13 272 combinations as an S (sensitivity)-S (synergy) plot (Fig 3B; Table S4 ). By applying a threshold of the 273 3 rd quantiles for CSS and S, we can clearly identify the most promising drug combinations that fulfill 274 both the sensitivity and synergy criteria, while avoiding the false positive drug combinations that 275 might be synergistic but do not achieve a sufficient high level of sensitivity. Taken together, the 276 combined use of CSS drug combination sensitivity score and its associated synergy score allows a 277 simultaneous evaluation of the sensitivity and synergy for a drug combination, which will facilitate 278 a more systematic analysis of high-throughput drug combination data with much less experimental 279 materials. 
378
The AUC is further normalized as the proportion of its theoretical upper bound according to:
380 where t is the minimum inhibition level that is considered meaningful (by default it is fixed at 10%, 381 assuming that the inhibition below 10% is experimental noise).
382
The CSS for the foreground drug is defined as a percentage and varies between 0 and 100:
As there are two drug combination dose-response curves depending on which drug is fixed 385 as the background drug, we refer to the results of Eq. (5) for either scenario as CSS 1 and CSS 2 , and 386 consider them as two samples that are generated from the same random variable. We take the 387 average of CSS 1 and CSS 2 as the CSS for the drug pair, i.e. 
471
For each of the four models, the synergy scores were determined first for a given dose 472 combination and then were averaged over the full dose-response matrix. With the four synergy 473 scores determined for each drug combination, the true synergistic and antagonistic drug 474 combinations are those with all the four synergy scores consistently higher than 5 and lower than 475 5, respectively. The aim was then to use the CSS-based synergy score which was determined by the 476 cross design data to predict the ground truth determined by the full dose-response matrix design.
477
The area under the ROC curve was used for evaluating how well the CSS-based synergy scores can 478 predict the consensus drug combinations determined using the full dose-response matrix data.
479
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